Introduction
In 1962, Landerman et al (1) demonstrated that the congenitally deficient plasma factor in patients with hereditary angioneurotic edema (HANE)is the inhibitor of plasma kallikrein. Prior to that work, Landeman (2) had reported on HANE patients and had reviewed other cases described in the literature (3) . From the viewpoint of inheritance and clinical outcome, he emphasized that edema of the larynx and pharynx leading to death from asphyxia was the characteristic, but uncommon symptom of this disease. In 1963, Donaldson and Evans (4) demonstrated that the congenitally deficient plasma factor in this disease was Cl-inhibitor (Cl-INH). In the same year, Kagan and Becker (5) proved that Landerman's kallikrein inhibitor corresponded to Cl-INH. In 1969, Donaldson et al (6) had subsequently postulated that C2-kinin (7, 8) was the permeability-enhancing substance generated in acute HANEattacks. Because a C 1-INH preparation has become clinically available (9-1 1), we assessed the in vivo function of this protein in acute HANEattacks. We demonstrated that its foremost function is inhibition of plasma kallikrein to generate bradykinin, which corresponds with HANE-kinin (12) (13) (14) (15) . At present, C l-INH is recognized as the regulator protein for the contact phase of the intrinsic coagulation cascade (16, 17) , Hageman factor (HF) homologue. In the activation of HF homologue, interactions between plasma proteinase systems occur (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
Consequently, biologically active polypeptides are liberated, resulting in the activation of cells in the blood and in the vascular endothelium (21) (22) (23) (24) (25) . In addition, the chief target tissues for edema attacks in HANEpatients (3) are those where blood supply is maintained by the microcirculation. In 1 960, Spaulding (26) demonstrated that methyltestosterone can maintain male HANEpatients in remission, although gynaecomastia (27) develops. At present, the attenuated androgen, danazol (28) , has proved to be useful for both sexes. Furthermore, Frank et al (29) pointed out that oral contraceptives can elicit acute attacks in younger female HANEpatients. We (14, 15) have also demonstrated that blood levels of estrone and estradiol modulate the frequency and severity of edema attacks in female HANE patients and that both hormones are elevated in male patients in remission. Although the effects of female sex hormoneson the circulatory system are still controversial (30), these hormones can regulate a number of catecholamine receptors in target organs (3 1 , 32 ). In addition, Donaldson and Evans (4) reported that amphetamines elicit edemaattacks in HANE patients. Furthermore, it has also been postulated that reactions mediated via the hypothalamoneurohypophyseal axis (19, 20) and via catecholamine release can modulatethe activation of plasma proteinase systems (33). Therefore, HANEappears a useful disease for analyzing the role of the autonomicnervous system and endocrine system in modulating activation of the plasma proteinases, especially in microcirculation.
On the basis of such pathophysiological findings, HANE patients can nowbe maintained in remission by synthetic inhibitors of activated plasma proteinase systems together with attenuated androgens (29). This has allowed them to survive long enough to evaluate the effects of aging on individuals under medical supervision, especially on female patients. Therefore, we continued clinical follow-up to determine whether the symptoms of acute attacks in female HANEpatients actually change with aging. Wefound that aging altered the features of acute attack of HANEfrom the occurrence of classical transient 
Patients and Methods

Twoelderly female patients
Died while being follow-up to evaluate age-dependent changes in the symptoms of acute attacks of HANE.The older one was in remission for nearly 20 years on oral tranexamic acid (tAMCHA) and danazol (100 mg once daily p.o.). After an acute attack ofileus-like colicky pain, she showedsymptomsof acute renal insufficiency, became unconscious, and soon died. The other patient suffered from acute circulatory shock, presumably caused by gram-negative bacterial infection. She had edema of the pharynx and larynx, anuria, and neuropsychiatric symptomsafter treatment of her circulatory shock, also resulting in a fulminant lethal course.
Methods In case No. 1, the coagulation status underwent emergency as ses sment, with inhibitory activity of Cl-INH and antithrombin-III (AT-III) being assayed automatically using a Cobas Fara (35) . In the second patient, progression was so rapid after the occurrence of edemathat measurementof the coagulation cascade could not be performed.
Case Reports
Case No. 1 A 67-year-old woman had her first attack of edema in the extremities at 15 years of age. At age 17, she had edema of the face and episodes of frequent colicky pain. These ileus-like attacks and severe colicky pain always resolved without any specific treatment. At age 47, she injured her gums, resulting in edema formation in the mouth. This acute attack was treated with Cl-INH concentrate. On the basis of the subsequent changes in the clinical and biochemical parameters, we concluded that C1-INH functions in vivo as a plasma kallikrein inhibitor and that HANE-kinin corresponds to bradykinin. Since then, she was maintained in remission on oral tAMCHA and danazol, with the exception of edemaformation in the soft tissues elicited by compression. Her last and fatal acute attack started in the morning of July 16, 1990 with ileus-like symptoms following overeating on the previous night. In the morning of July 17, anuria occurred and she was admitted to the Emergency Center of Senri near Osaka. In the afternoon, the blood level of Cl-INH was 15%, so 1,500 units of a Cl-INH preparation was given intravenously and the inhibitory activity recovered to 77%. However, the AT-III activity was found to be 55%at the same time. In the afternoon of July 18, she lost consciousness and activity of AT-III decreased to 35% (36). In the evening, she died after a fulminant course of 50 hours from onset.
Case No. 2 A 53-year-old womanwas diagnosed as HANEat age 48 by a family study. She had suffered from acute attacks of edema of the extremities at a young age, but had remained in remission after menopausewithout any specific medication. In midDecember 1990, she suffered from severe influenza and lost her appetite. On December 22, her consciousness became cloudy and in the night of December 23 she went into shock. She was admitted to Saiseikai Izuo Hospital as an emergency patient. On admission, the blood pressure was 80/46 mmHg,the pulse rate was 96/min, and her temperature was 35.9°C. She could answer questions, but was hypokinetic. There were no neurological signs and no specific findings on physical examination. Radiological examination of the chest and abdomen, computed tomography of the brain and electrocardiogram (ECG) were not helpful. Ultrasound of the abdomenshowed a silent gall stone. There was leukocytosis (24, 
Discussion
Despite treatment by Cl-INH with or without a synthetic inhibitor, these 2 elderly female HANEpatients died of disseminated intravascular coagulation (DIC) or multiple organ failure (MOF)following an acute attack, showing a fulminant lethal course. Mineshita et al (34) reported a younger (36-yearold) female HANEpatient, who developed DIC during treatment of a urinary tract infection and then suffered from acute edema. Her edema was improved by treatment with gabexate mesilate alone and the decrease in AT-III was only 79%. This slight decrease of AT-III appears analogous to the phenomena observed during remission of our younger patients (12) . The main difference between our case 1 and the case of Mineshita et al (34) was the rapid and profound decrease of AT-III, which was not improved by C1-INH and was soon fatal (36). Our case 2 and Mineshita' s case developed an acute attack in the course of treatment for bacterial infection or circulatory shock. Lipopolysaccharide (LPS) (37) released by gram-negative bacteria and catecholamine derivatives (19, 20, 33) 
